More recently, several molecular-targeted agents such as the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib have emerged for treatment of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.